跳至主要内容
临床试验/EUCTR2009-011541-24-FR
EUCTR2009-011541-24-FR进行中(未招募)1 期

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study - ADAGIO Follow-Up

Teva Pharmaceutical Industries Ltd0 个研究点目标入组 700 人开始时间: 2009年6月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1)Subjects who participated in the ADAGIO study, and who entered the active phase of the study and
  • 2)Subjects who are currently on rasagiline treatment (or subjects who have stopped rasagiline treatment, are willing to restart treatment, and in the opinion of the investigator will gain clinical benefit from restarting treatment) and
  • 3)Subjects with a diagnosis of Parkinson’s disease and
  • 4)Subjects willing and able to give written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1)Subjects who have discontinued rasagiline treatment due to an adverse event and have not restarted rasagiline treatment subsequently.
  • 2)Subjects who cannot be given rasagiline due to any exclusion based on the local label (including pregnancy or nursing women) or due to the use of medications contraindicated for concomitant use with rasagiline according to local label
  • 3)Subjects with a medical condition that is considered by the investigator as significant enough to prevent participation

研究者

发起方
Teva Pharmaceutical Industries Ltd

相似试验

An Open-Label, Multi-Center, Follow-Up Study... | 临床试验